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Summary
Genetic screens are powerful tools for identifying genes responsible for diverse phenotypes. Here 
we describe a genome-wide CRISPR-Cas9-mediated loss-of-function screen in tumor growth and 
metastasis. We mutagenized a non-metastatic mouse cancer cell line using a genome-scale library 
with 67,405 single guide RNAs (sgRNAs). The mutant cell pool rapidly generates metastases 
when transplanted into immunocompromised mice. Enriched sgRNAs in lung metastases and late 
stage primary tumors were found to target a small set of genes, suggesting specific loss-of-
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function mutations drive tumor growth and metastasis. Individual sgRNAs and a small pool of 624 
sgRNAs targeting the top scoring genes from the primary screen dramatically accelerate 
metastasis. In all of these experiments, the effect of mutations on primary tumor growth positively 
correlates with the development of metastases. Our study demonstrates Cas9-based screening as a 
robust method to systematically assay gene phenotypes in cancer evolution in vivo.
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Introduction
Cancer genomes have complex landscapes of mutations and diverse types of genetic 
aberrations (Lawrence et al., 2013; Weinberg, 2007). A major challenge in understanding 
the cancer genome is to disentangle alterations that are driving the processes of tumor 
evolution from passenger mutations (Garraway and Lander, 2013). Primary tumor growth 
and metastasis are distinct yet linked processes in the progression of solid tumors (Nguyen 
et al., 2009; Valastyan and Weinberg, 2011; Vanharanta and Massague, 2013). It has been 
observed in the clinic that the probability of detecting metastases in a patient positively 
correlates with the size of a primary tumor (Heimann and Hellman, 1998). Several possible 
explanations have been suggested: metastatic properties may only be acquired in late-stage 
tumors; larger tumors proportionally seed more cells into circulation that eventually migrate 
to other sites; or that cells with a strong ability to proliferate also have enhanced ability to 
metastasize (Weinberg, 2007). In early studies using random insertional mutagenesis, it was 
observed that metastatic cell subpopulations overgrow to complete dominance in the 
primary tumor, suggesting progressive selection at both sites (Korczak et al., 1988; 
Waghorne et al., 1988).
Genetic screens are powerful tools for assaying phenotypes and identifying causal genes in 
various hallmarks of cancer progression (Hanahan and Weinberg, 2011). RNA interference 
(RNAi), or overexpression of open reading frames (ORFs), have been utilized for screening 
cancer genes in several models of oncogenesis in mice (Schramek et al., 2014; Shao et al., 
2014; Zender et al., 2008). Recently, the Cas9 nuclease (Barrangou et al., 2007; Bolotin et 
al., 2005; Chylinski et al., 2013; Chylinski et al., 2014; Deltcheva et al., 2011; Garneau et 
al., 2010; Gasiunas et al., 2012; Jinek et al., 2012; Sapranauskas et al., 2011) from the 
microbial type II CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) 
system has been harnessed to facilitate loss-of-function mutations in eukaryotic cells (Cong 
et al., 2013; Mali et al., 2013). When the Cas9 nuclease is targeted to specific locations in 
the genome, DNA cleavage results in double-stranded breaks (DSBs), which are repaired via 
non-homologous end-joining (NHEJ) (Rouet et al., 1994). NHEJ repair results in insertion 
or deletion (indel) mutations that can cause loss-of-function if the DSB occurs in a coding 
exon. The Cas9 nuclease can be guided to its DNA target by a single guide RNA (sgRNA) 
(Jinek et al., 2012), a synthetic fusion between the CRISPR RNA (crRNA) and trans-
activating crRNA (tracrRNA) (Deltcheva et al., 2011). In cells, Cas9-mediated gene 
disruption requires the full-length tracrRNA (Cong et al., 2013; Mali et al., 2013), in which 
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secondary structures at the 3′ end of tracrRNA are critical for Cas9-mediated genome 
modification (Cong et al., 2013; Hsu et al., 2013).
Screens utilizing Cas9 have identified genes that are essential for cell survival and genes 
involved in drug resistance in various cell lines (Koike-Yusa et al., 2014; Shalem et al., 
2014; Wang et al., 2014; Zhou et al., 2014). In vivo pooled screens are challenging due to 
many factors, such as the complexity of the library, limitations of virus delivery and/or cell 
transplantation, uniformity of viral transduction at a low multiplicity of infection (MOI), and 
the complex dynamics and interactions of cells in animals. In this study, we report a 
genome-wide Cas9 knockout screen in a mouse model of tumor evolution. This screen 
provides a systematic phenotypic measurement of loss-of-function mutations in primary 
tumor growth and metastasis.
Results
CRISPR/Cas9 library-mediated mutagenesis promotes metastasis
We derived and cloned a cell line (Chen et al., 2014) from a mouse non-small cell lung 
cancer (NSCLC) (Kumar et al., 2009). This cell line possesses an oncogenic Kras in 
conjunction with homozygous p53 and heterozygous Dicer1 loss of function (KrasG12D/
+;p53−/−;Dicer1+/−, denoted KPD), and is capable of inducing tumors when transplanted 
into immunocompromised mice (Chen et al., 2014; Kumar et al., 2009). We transduced this 
cell line with a lentivirus carrying a Cas9 transgene fused to a green fluorescent protein 
(GFP) and generated clonal cell lines (Cas9-GFP KPD) (Experimental Procedures) (Figure 
S1 A–B). A clonal Cas9-GFP KPD cell line (clone 5) was selected to provide genetic and 
cellular homogeneity for subsequent screens.
We utilized a pooled genome-wide mouse sgRNA library (termed mouse Genome-scale 
CRISPR knockout library A, or mGeCKOa) containing 67,405 sgRNAs targeting 20,611 
protein-coding genes and 1,175 microRNA precursors in the mouse genome (Sanjana et al., 
2014). The library also contains 1,000 control sgRNAs (termed non-targeting sgRNAs) 
designed to have minimal homology to sequences in the mouse genome (Sanjana et al., 
2014; Shalem et al., 2014). We transduced the Cas9-GFP KPD cell line with mGeCKOa 
with three independent infection replicates and each replicate with greater than 400x library 
coverage (cells per lentiviral CRISPR construct) (Figure 1A) (Experimental Procedures).
After in vitro culture for 1 week, we subcutaneously transplanted 3 x 107 cells into the 
flanks of immunocompromised Nu/Nu mice (Figure 1A). We transplanted the cells from 
each infection replicate into 4 mice, using 1 mouse for early tumor sequencing and 3 mice 
for sequencing of late stage primary tumor and metastases (Figure 1A). Both mGeCKOa 
transduced and untransduced Cas9-GFP KPD cells formed tumors at the injection site 
(Figure 1B). Like most subcutaneously transplanted tumors, these tumors were poorly 
differentiated. The primary tumors induced by mGeCKOa transduced cells grew slightly 
faster than tumors from the untransduced cells at an early stage (Figure 1C) (two weeks 
post-transplantation) (paired two-tailed t-test, p = 0.05), but at late stages all tumors were 
similar in size (paired two-tailed t-test, p = 0.18 for data at four weeks, and p = 0.6 for data 
at six weeks) (Figure 1C).
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At 6 weeks post-transplantation, we imaged the mice using micro-computed tomography 
(μCT), and found tumors in the lungs of the mice transplanted with mGeCKOa-transduced 
Cas9-GFP KPD cells (mGeCKOa mice), but not in the mice transplanted with untransduced 
Cas9-GFP KPD cells (control mice) (Figure 1D, Figure S1 C). Mice were sacrificed and 
examined for metastases in various organs. Under a fluorescent stereoscope at 6x 
magnification, metastases were visually detected in the lung in 90% (8/9) of the mGeCKOa 
mice (Figure S1 D). The mGeCKOa mice on average had 80% of their lung lobes positive 
for metastases (Figure 1E). In contrast, none (0/3) of the control mice developed detectable 
metastases in the lung (Figure 1E). At this time, metastases were not detected in the liver, 
kidney or spleen in either group (Figure 1F). These data indicated that mGeCKOa library 
transduction enhanced the ability of the Cas9-GFP KPD cells to form metastases in the lung.
Dynamic evolution of sgRNA library representation during tumor growth and metastasis
To investigate the sgRNA representation through different stages of tumor evolution and to 
identify genes where loss-of-function confers a proliferative or metastatic phenotype, we 
used deep sequencing to read out the sgRNA representation. At six weeks post 
transplantation, we sequenced the late stage primary tumor and three random lobes from the 
lung of each of the nine mGeCKOa mice (Figure 1A) (Experimental Procedures). In 
parallel, we also sequenced the mGeCKOa input plasmid library, the pre-transplantation 
mGeCKOa transduced Cas9-GFP KPD cells (cultured in vitro for 7 days after transduction), 
as well as early stage primary tumors (two weeks post transplantation, one mouse from each 
infection replicate). In the cell samples, the sgRNA representations showed high 
concordance between technical replicates (correlation, ρ = 0.95 on average, n = 3) and 
biological infection replicates (correlation, ρ = 0.84 on average, n = 3) (Figure 2A, Figure S2 
A, B, E). The sgRNA representation of cell samples highly correlates with the plasmid 
representation (correlation, ρ = 0.93 on average, n = 3) (Figure 2A, Figure S2 C, E). 
Furthermore, different sgRNAs that target the same gene are correlated in terms of rank 
change (correlation, ρ = 0.49 on average, n = 3) (Figure S2 D). Using Gene Set Enrichment 
Analysis, we found that the sgRNAs with significantly decreased abundance in cells 
compared to plasmid are enriched for genes involved in fundamental cellular processes, such 
as ribosomal proteins, translation factors, RNA splicing factors and RNA processing factors, 
indicating selection against the loss of these genes after one week in culture (Figure S2 F).
To investigate the sgRNA library dynamics in different sample types (plasmid, pre-
transplantation cells, early primary tumor, late primary tumor, and lung metastases), we 
compared the overall distributions of sgRNAs from all samples sequenced. Cell samples 
tightly clustered with each other and the plasmid, forming a cell-plasmid clade (Figure 2A, 
Figure S2 E). Early primary tumor samples also clustered with each other and then with the 
cell-plasmid clade, whereas late tumors and lung metastases clustered together in a distinct 
group (Figure 2A, Figure S2 E). The overlap of detected sgRNAs between different pre-
transplantation infection replicates is over 95% (Figure S3 A). The detected sgRNAs in the 
three infection replicates of early tumor samples overlap 63 – 76% with each other (Figure 
S3 B). Early primary tumors retained less than half (32 – 49%) of the sgRNAs found in the 
transplanted cell populations (Figure 2B–C, Figure S3 C–D). Compared to the cell 
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populations, sgRNAs whose targets are genes involved in fundamental cellular processes are 
further depleted in early tumors (Table S1).
Interestingly, only a small fraction of sgRNAs (less than 4% of all sgRNAs, or less than 8% 
of sgRNAs in the early primary tumor of the corresponding replicate) were detected in the 
late stage primary tumor samples (Figure 2B–C, Figure S3 C–D). The sgRNA diversity (i.e. 
number of different sgRNAs detected) further decreased in samples from lung metastases 
(Figure 2B–C, Figure S3 C–D). The lung samples retained ≤ 0.4% of all sgRNAs in the 
mGeCKOa library, or ≤ 1.1% of sgRNAs found in the early primary tumor of the 
corresponding replicate, with a subset of highly enriched sgRNAs (Figure 2B–C, Figure S3 
C–D). The global patterns of sgRNA distributions in different sample types are distinct, as is 
evident in the strong shifts in the respective cumulative distribution functions (Kolmogorov-
Smirnov (KS) test, p < 10−15 for all pairwise comparisons) (Figure 2D).
Enriched sgRNAs in primary tumors
Late primary tumors retain few sgRNAs (on average 813 ± 264 sgRNAs, n = 9 mice), with 
even fewer at high frequencies (4 ± 1 sgRNAs with > 5% of total reads) in each mouse 
(Figure 2B–C, Figure S2 C–D, Figure 3A, Figure S4 H). We used three methods to identify 
enriched sgRNAs in the late primary tumor: (1) sgRNAs above a certain threshold, (2) top 
ranked sgRNAs in the tumor of each mouse, and (3) using the false discovery rate (FDR), 
i.e. sgRNAs enriched compared to the distribution of the 1,000 non-targeting sgRNAs. All 
three methods generated similar results (Figure S4 A). Taking the results from (3) as an 
example, a total of 935 sgRNAs (targeting 909 genes) are enriched over the non-targeting 
controls (FDR cutoff = 0.2%) in the late primary tumor of one or more mice (Figure 3B–C). 
These sgRNAs are targeting genes highly enriched in apoptosis pathways (Table S2), with 
many of them being pro-apoptotic, such as BH3 interacting-domain death agonist (Bid), 
Phosphatase and Tensin Homolog (Pten), Cyclin-dependent kinase inhibitor 2a (Cdkn2a), 
and O-6-Methylguanine-DNA Methyltransferase (Mgmt), suggesting strong selection for 
mutations that inactivate apoptosis in primary tumor cells.
We identified 24 candidate genes that were targeted by two or more independent sgRNAs 
enriched in late primary tumors (Figure 3B–C). These genes were found to be mutated in 
patients in many previously reported cancer sequencing studies curated by cBioPortal 
(Cerami et al., 2012; Gao et al., 2013) (Figure S5 A). For example, in somatic mutations 
identified by The Cancer Genome Atlas (TCGA) for non-small cell lung cancer (NSCLC), 
including adenocarcinoma (LUAD) (TCGA-Network, 2014) and lung squamous cell 
carcinoma (LUSC) (TCGA-Network, 2012), 36% (107/407) of the patients have one or 
more of these 24 genes mutated (Figure S5 B–C). Several candidates were well-known 
tumor suppressors, such as Pten, Cyclin-dependent kinase inhibitor 2b (Cdkn2b), 
Neurofibromin 2 (Nf2, Merlin), Alpha-type platelet-derived growth factor receptor (Pdgfra), 
and Integrin alpha X (Itgax).
Enriched sgRNAs in metastases
We also sequenced the sgRNA distributions from three lung lobes for each mouse 
transplanted with mGeCKOa-transduced Cas9-GFP KPD cells. In each lobe, the sgRNA 
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representation is dominated by one or a few sgRNAs (Figure 4A, Figure S3 D, Figure S4 I). 
In each mouse, the lung sgRNA representation (average of normalized sgRNA 
representations from three lobes) is also dominated by a small number of sgRNAs (on 
average, 3.4 ± 0.4 sgRNAs with > 5% of total reads) (Figure 4B), suggesting that metastases 
were seeded by a small set of cells, which grew to dominance over this time scale. Non-
targeting sgRNAs were occasionally detected in the metastases, but never observed at high 
frequency (< 0.1% of total reads in any lobe; Figure 2C, Figure 4A–B, Figure S4 I). These 
observations are consistent with our finding that untransduced tumors are not metastatic 
(Figure 1E), suggesting specific sgRNA-mediated mutations led to metastasis.
The sgRNA representations in the lung metastases are similar to those in the late stage 
primary tumors in several ways. First, the detected sgRNAs in lung samples significantly 
overlap with those in late tumor samples (Chi-square test, p < 10−15) (Figure S3 E). Second, 
the number of sgRNAs detected in lung samples correlates, albeit weakly, with the number 
of sgRNAs detected in late primary tumor samples (ρ= 0.42, F-test, p = 0.097) (Figure S3 
F). Third, the abundance (number of reads) of sgRNAs in the lung positively correlates with 
that in the late primary tumors of the same mouse (correlation, ρ = 0.18 on average, F-test, p 
< 0.01, n = 9) (Figure S3 G). Fourth, in most mice (8/9), the lung metastasis enriched 
sgRNAs also occupy a large fraction of reads in the late primary tumor of the same mouse 
(Figure 4C, left panel), significantly larger than a random sampling of the same number of 
sgRNAs from the mGeCKOa library (Figure 4C, right panel). These data indicate that 
mutants with preferential ability to proliferate in late primary tumors are more likely to 
dominate the metastases.
The three methods (threshold, rank, or FDR) of finding enriched sgRNAs in the lung 
metastases yield similar results (Figure S4 B). Using the non-targeting sgRNA distribution 
to set a FDR-based cutoff for enrichment, the enriched sgRNAs in different lobes of the 
same mouse overlap with each other by 62% ± 5% (Chi-square test, p < 10−15) (Figure S4 
C), while different mice show greater variability while still overlapping significantly (29% ± 
3% Chi-square test, p < 10−15) (Figure S4 D). The overlap between sgRNAs in different 
biological / infection replicate experiments when pooling enriched sgRNAs from all mice in 
the same replicate is 54% (Chi-square test, p < 10−15) (Figure S4 E), suggesting pooling 
sgRNAs from mice in the same experiment facilitates the identification of shared hits. These 
data suggest that the three independent experiments reproducibly captured a common set of 
hits, and provides a picture for in vivo experimental variation between different lobes, 
different animals and different infection replicates.
We found 147 sgRNAs enriched in more than one lobe, and 105 sgRNAs enriched in the 
lung of more than one mouse (Figure 4D–E). These include sgRNAs targeting Nf2, Pten, 
Tripartite motif-containing protein 72 (Trim72), Fibrinogen Alpha Chain (Fga), Bid, 
Cyclin-dependent kinase inhibitor 2a (Cdkn2a), Zinc Finger FYVE Domain Containing 28 
(Zfyve28), Reproductive homeobox 13 (Rhox13), BRISC and BRCA1 A complex member 1 
(Babam1), as well as microRNA genes miR-152 and miR-345. Intriguingly, a few sgRNAs 
targeting the Pol II subunits and olfactory receptor are also enriched in the lung, possibly 
due to off-target effects or unknown roles of these genes. For most sgRNAs detected in lung 
metastases, the relative abundance in metastases is lower than that in the late primary tumor 
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of the same mouse, with a metastasis-primary ratio (MPR) less than 1 (Figure S4 F), likely 
due to more skewed distributions of sgRNAs in the metastases compared to those in the late 
primary tumors. A small subset of sgRNAs, however, are more abundant in metastases than 
in primary tumors (MPR > 1) in multiple mice (e.g. sgRNAs targeting Nf2, Trim72, 
Prostaglandin E Synthase 2 (Ptgse2) or Ubiquitin-conjugating enzyme E2G 2 (Ube2g2)) 
(Figure 4F).
For four genes, Nf2, Pten, Trim72, and Zfyve28, two independent sgRNAs targeting different 
regions of the same gene were enriched in lung metastases (Figure 4G). One of the Zfyve28-
targeting sgRNAs, however, is enriched in only one mouse; whereas Nf2, Pten and Trim72 
all have two sgRNAs enriched in multiple mice (Figure 4H). These three genes, several 
representative genes with one frequently enriched sgRNA (Cdkn2a, Fga, Cryba4), and the 
top two scoring microRNAs (miR-152 and miR-345) were chosen to assay individually for 
primary tumor growth and metastases formation.
Validation in vivo using individual sgRNAs
For these eight genes (Nf2, Pten, Trim72, Cdkn2a, Fga, Cryba4, miR-152 and miR-345), we 
cloned multiple sgRNAs targeting each of them into the lentiGuide-Puro vector, and 
transduced them into the Cas9-GFP KPD cell line (Figure 5A) (Experimental Procedures). 
As expected, these sgRNAs generated a broad distribution of NHEJ-mediated indels at the 
target site when examined three days post-transduction, with a bias toward deletions (Figure 
5B). For protein coding genes, the majority (> 80%) of indels are out-of-frame, which 
potentially disrupt the protein functions. For miR-152 and miR-345, the sgRNAs generated 
mostly deletions (> 90% of indels are deletions, average indel size = −7 bp) (Figure 5B), 
overlapping with the loop or mature microRNA sequences in the hairpins, which are 
structures required for maturation of microRNAs. For proteins where specific antibodies are 
available (Nf2 and Pten), we found that the majority of the protein products were 
significantly reduced one week after lentiviral sgRNA infection (Figure S6 A).
When these single-sgRNA-transduced cells were transplanted into the flanks of 
immunocompromised mice, they all formed tumors in situ. With two mice injected per 
sgRNA and three sgRNAs per gene, all genes tested showed increased lung metastasis 
formation compared to controls (untransduced and non-targeting sgRNAs), with the most 
significant ones being Nf2, Pten and Cdkn2a (Fisher’s exact test, one-tailed, p < 10−3) 
(Figure 5C–D). Fga and Trim72 also have effects on metastasis acceleration (Fga: p = 
0.001, Trim72: p = 0.046). Cryba4 is not statistically different from controls (p = 0.1). Both 
microRNAs targeted significantly increased metastasis (miR-345: p = 0.01, miR-152: p = 
0.046). These data suggest that loss-of-function mutations in any of Nf2, Pten, Cdkn2a, 
Trim72, Fga, miR345 or miR-152 are sufficient to accelerate the rate of metastasis formation 
in this genetic background.
Most genes targeted by single sgRNAs also contributed to accelerated primary tumor growth 
compared to controls (Figure 5E). Nf2 and Pten loss-of-function dramatically sped up tumor 
growth (KS test, p < 0.001) (Figure 5E); Cdkn2a-, Trim72- and Fga- targeting sgRNAs 
slightly accelerate primary tumor growth (KS test, p = 0.003 – 0.01); Cryba4 has a marginal 
effect (KS test, p = 0.08); neither miR-152- nor miR-345- targeting sgRNAs promote 
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primary tumor growth (KS test, p > 0.1). Overall, for the targets we examined using 
individual sgRNAs, the number of lobes with lung metastases strongly correlates with the 
terminal volume of the late primary tumor (or average primary tumor growth rate) 
(correlation, ρ = 0.83, F-test, p < 0.01) (Figure 5F), indicating at a single gene level that 
mutant cells with a stronger ability to promote primary tumor growth generate metastases 
faster.
To analyze blood samples for the presence of circulating tumor cells (CTCs), we designed a 
microfluidic device based on the physical size of the Cas9-GFP KPD cells (Figure S6 B–C). 
We performed CTC capture with terminal blood samples from mice injected with Cas9-GFP 
KPD cells transduced with sgRNAs targeting Nf2, Pten, Trim72, Cdkn2a, miR-152 and 
control cells (uninfected or non-targeting sgRNA) (Figure S6 C–D). Mice transplanted with 
cells transduced with sgRNAs targeting Nf2, Pten, Trim72, Cdkn2a or miR-152 had a higher 
concentration of CTCs as compared to controls (Figure S6 D–G), consistent with the higher 
rate of lung metastasis formation.
Competitive dynamics of top hits assessed using an sgRNA minipool
To better understand the relative metastatic potential of multiple genes from our genome-
wide screen, we designed a targeted pooled screen with a smaller library. This small library 
(termed validation minipool) contains 524 sgRNAs targeting 53 genes which had highly 
enriched sgRNAs in lung metastases in the genome-wide screen (10 sgRNAs per gene for 
most genes) plus 100 non-targeting sgRNAs. We also created a size-matched library 
containing 624 non-targeting sgRNAs (termed control minipool) (Figure 6A). Lentiviruses 
from these two pools were used to transduce the Cas9-GFP KPD cells, which were then 
cultured in vitro for one week, and then transplanted into Nu/Nu mice (Figure 6A). Both 
validation minipool and control minipool transduced cells induced primary tumor growth at 
a similar rate (Figure 6B). However, mice transplanted with validation minipool cells had a 
dramatically elevated rate of lung metastasis formation (Figure 6C).
We sequenced the validation minipool plasmid library, the transduced cells pre-
transplantation, as well as the late stage primary tumors and whole lungs of the mice at 5 
weeks post-transplantation. The sgRNA representations correlate strongly between technical 
replicates of the transduced cell pool, late primary tumor and lung metastases (Figure S7 A, 
D). The sgRNA representation in the cell sample strongly correlated with the plasmid 
(correlation, ρ = 0.91) (Figure S7 B, D). Almost all (99.4%) sgRNAs were recovered in the 
plasmid and the cell population (Figure S7 C). The late primary tumors retained less than 
half of the sgRNAs, while the metastases in the whole lung only retained a small fraction (2 
– 7%) of all sgRNAs (Figure S7 C). Enriched sgRNAs from lung metastases clustered with 
each other and with late primary tumors (Figure S7 D). Similar to the genome-wide library, 
in this validation minipool, the plasmid and cell samples had a unimodal distribution of 
sgRNAs, whereas the late primary tumors and lung metastases contained a bi-modal 
distribution, with the majority of sgRNAs being absent and a small fraction spanning a large 
range of non-zero read counts (Figure 6D). Intriguingly, two mice retained relatively high 
sgRNA diversity in late primary tumors (Figure 6D), likely due to dormant or slowly 
proliferating cells that remained in low numbers during tumor growth. Similar to the 
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genome-wide library, large shifts in the sgRNA distribution exist between different sample 
types (KS test, p < 10−15 for pairwise comparisons between the cell, primary tumor and lung 
metastases, p = 0.02 between plasmid and cell) (Figure 6E).
In the validation minipool, the sgRNAs detected in the late primary tumors or the lungs of 
five different mice significantly overlap with each other (Figure S7 E–F). The late primary 
tumors and lung metastases are dominated by a few sgRNAs (Figure 7A, Figure S7 G–I), 
suggesting these sgRNAs outcompete others during tumor growth and metastasis. In this 
small size validation library, the sgRNA representations are highly correlated between late 
primary tumors and lung metastases (correlation, ρ = 0.55 on average, F test, p < 0.01, n = 5) 
(Figure 7B). The late primary tumors and lung metastases have dozens of sgRNAs at 
moderate to high frequencies (Figure 7B–C). Several genes have multiple independent 
sgRNAs that are enriched in the lung over the primary tumor (MPR > 1), such as Nf2 (8 
sgRNAs), Pten (4 sgRNAs), Trim72 (3 sgRNAs), Ube2g2 (3 sgRNAs), Ptges2 (2 sgRNAs) 
and ATP-dependent DNA Ligase IV (Lig4) (2 sgRNAs) (Figure 7C–D). Two Cdkn2a 
sgRNAs were present in both late primary tumors and lung metastases in two mice, but with 
MPR < 1. Fga-, Cryba4-, miR-152- or miR-345- targeting sgRNAs were not found at high 
frequency in either late primary tumors or lung metastases, which suggests that they are 
outcompeted by other loss-of-function mutations (such as Nf2), which agrees with the 
relatively reduced metastasis formation of these genes in the individual sgRNA validation. 
These results further validate several of the top hits from the primary screen, using either 
sgRNA dominance (e.g. Nf2, Pten, Trim72) or MPR (e.g. Nf2, Trim72, Ube2g2, Ptges2). 
This validation minipool reveals the dynamics of multiple competing mutants chosen from 
the primary screen hits, and indicates that mutants with strong pro-growth effects tend to 
enhance metastases (Figure 7E).
TCGA gene expression of screen hits in human lung cancer
To assess the relevance of our mGeCKOa and validation minipool screen hits (genes 
targeted by sgRNAs enriched in lung metastases) to pathological metastasis in human 
cancer, we performed gene expression analysis of the human orthologs of these genes. We 
compared mRNA levels in metastatic compared to non-metastatic primary tumors in patients 
samples using TCGA mRNA sequencing data. We found that most (61 – 75%) of these 
genes are downregulated in metastatic tumors in non-small cell lung cancer patients (Figure 
S5D–E, Table S6). These data suggest that downregulation of these genes is selected for in 
metastatic tumors from patients.
Discussion
Pooled mutagenesis in a metastasis model
Distal metastases develop as primary tumors shed circulating tumor cells (CTCs) into the 
circulation, from which CTCs travel to the destination site, move out of the blood vessels 
and initiate clonal growth (Valastyan and Weinberg, 2011; Vanharanta and Massague, 2013; 
Weinberg, 2007). In this study, cancer cells transplanted into the flanks of mice form 
primary tumors in situ, and cells from this mass undergo the intravasation – circulation - 
extravasation - clonal growth cascade to form distal metastases (Francia et al., 2011). The 
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initial lung cancer cell line has little capacity to form metastases; in contrast, after being 
mutagenized with the mGeCKOa genome-scale Cas9 knockout library, the cell population 
form highly metastatic tumors. Thus, these mutations, acting in simple or complex, 
pleiotropic ways, accelerate metastasis. In this model, the effect of mutations on metastasis 
strongly correlates with their abundance in late stage primary tumors.
SgRNA dynamics during tumor evolution
The dynamics of the sgRNA population changed dramatically over the course of tumor 
development and metastasis, reflecting the selection and bottlenecks of cellular evolution in 
vitro and in vivo. After a week in culture, cells retained most of the sgRNAs present in the 
plasmid library, with decreases in sgRNAs targeting genes involved in fundamental cellular 
processes. The distribution of non-targeting control sgRNAs is almost identical to those 
targeting genes, suggesting that the selective pressure of in vitro culture alone does not 
radically alter sgRNA representation, which is similar to previous observations in human 
melanoma cells (Shalem et al., 2014).
In contrast, less than half of the sgRNAs survive in an early stage primary tumor. This loss 
of representation occurs with both gene-targeting sgRNAs and non-targeting control 
sgRNAs, suggesting that random-sampling influences the sgRNA dynamics during the 
transplantation and tumor initiation processes, although we cannot exclude that some of the 
non-targeting sgRNAs might have detrimental or pro-growth effects. We also detected 
further dropout of genes involved in fundamental cellular processes in early tumor samples 
compared to cell samples. Thus, it is likely that the sgRNA dynamics are influenced by a 
combination of selection and random sampling during transplantation and tumor initiation.
As primary tumors grow, the mutant cells proliferate and compete as a pool. This creates 
strong selection for sgRNAs targeting anti-apoptotic genes and other tumor suppressors. The 
majority of the genetic diversity in early tumors is lost during the subsequent 4 weeks of 
primary tumor growth. Accordingly, sequencing revealed a smaller set of dominant 
sgRNAs, usually on the order of hundreds to a few thousand per mouse. In addition, almost 
all of non-targeting sgRNAs are lost during primary tumor growth, which is consistent with 
selection for cells with special growth and survival properties. This observation is also 
consistent with earlier transplantation studies by Kerbel and colleagues using small pools of 
randomly mutagenized cells, which found that the majority of clonal variants detectable by 
Southern blot disappeared within six weeks of primary tumor growth, leaving one dominant 
clone (Korczak et al., 1988; Waghorne et al., 1988).
Each step towards metastasis acts as a bottleneck. In the lung metastases, we detected very 
few sgRNAs at high abundance. As with the primary tumor, we find only a few non-
targeting sgRNAs at low frequencies in metastases. Their presence could be due to unknown 
off-target effects of these sgRNAs, or random shedding of CTCs in the primary tumor, or 
clustering together with other strongly selected CTCs during metastasis (Aceto et al., 2014).
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Relevance of screen hits to human cancer
Several of the genes enriched in late stage primary tumors are associated with cancer, but 
their functions in tumor growth are poorly understood. For example, Mgmt, a gene with two 
enriched sgRNAs, is required for DNA repair and thus crucial for genome stability (Tano et 
al., 1990). Mutation, silencing or promoter methylation of MGMT is associated with primary 
glioblastomas (Jesien-Lewandowicz et al., 2009). Med16, another gene with two enriched 
sgRNAs, encodes a subunit of the mediator complex of transcription regulation, which has 
been recently implicated in cancer (Huang et al., 2012; Schiano et al., 2014).
We found that the genes that are significantly enriched in lung metastases largely overlap 
with those found in abundance in the late primary tumor. Several of these hits were 
validated in vivo using multiple individual sgRNAs, including Nf2, Pten, Cdkn2a, Trim72, 
Fga, miR-152 and miR-345. Nf2, Pten and Cdkn2a are well-known tumor suppressor genes. 
Intriguingly, the NF2 locus is only mutated at a 1% frequency in primary tumors of human 
NSCLC patients (LUAD and/or LUSC) (TCGA-Network, 2012, 2014). It is possible that 
NF2 mutations influence metastases to a greater degree than primary tumor growth, but this 
awaits metastasis genomics from patient samples. Pten mutations are also associated with 
advanced stages of tumor progression in a mouse model of lung cancer (McFadden et al., 
2014), and PTEN was found mutated at 8% in adenocarcinoma patients (LUAD). CDKN2A 
has been shown to be often inactivated in lung cancer (Kaczmarczyk et al., 2012; Yokota et 
al., 2003). For Trim72 (an E3 ubiquitin ligase) and Fga (the extracellular matrix protein 
fibrinogen involved in blood clot formation), there is little information associating them to 
metastasis or cancer. Studies have shown that miR-152 and miR-345 are associated with 
cancer and metastasis (Cheng et al., 2014; Tang et al., 2011). FGF2 and BAG3, which 
promote metastasis, were predicted targets of miR-152 and miR-345, thus loss of these 
microRNAs may lead to acceleration of metastases likely due to de-repression of these 
genes (Cheng et al., 2014; Tang et al., 2011).
In our own analysis of TCGA samples from lung cancer patients, we observed 
downregulation of the human orthologs of the genes identified in the genome-wide and 
validation minipool screens at the mRNA level in metastatic tumors compared to non-
metastatic tumors (Figure S5D–E, Table S6, Supplemental Results and Discussion), 
suggesting that these genes may also be inactivated during pathological metastasis. Human 
orthologs of these genes are often found mutated in cancers (Figure S5A–C). Moreover, 
these genes have been implicated in various pathways and biological processes in 
tumorigenesis and/or metastasis in human cancer (Table S7A–C). However, most cancer 
sequencing studies involve samples from primary tumors of patients. In the clinic, 
metastases are rarely sampled. Future patient sequencing directly from metastases may 
further connect genes identified in the mouse model to those mutated or silenced in clinical 
metastases.
Future in vivo functional genomic screens
Our study provides a roadmap for in vivo Cas9 screens and future studies can take advantage 
of this model to explore other oncogenotypes, delivery methods or metastasis target organs. 
Genome-scale CRISPR screening is feasible using a transplant model with virtually any cell 
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line or genetic background (e.g. mutations in EGFR, KRAS, ALK, etc.), including a large 
repertoire of human cell lines from diverse cancer types (Barretina et al., 2012). Other cell 
delivery methods, such as intravenous injection or orthotopic transplantation, may help 
identify genes regulating extravasation and clonalization. Examining samples from other 
stages or sites, such as CTCs or metastases to other organs can provide a more refined 
picture of tumor evolution.
In addition to these parameters, several aspects of the screen perturbations themselves can 
also be modified. Targeted drug therapies or immunotherapies can be applied in conjunction 
with the in vivo screening strategy to identify genes involved in acquired resistance. Recent 
advances in screen technology, such as Cas9-mediated activation (Gilbert et al., 2014; 
Konermann et al., 2014), may be used to identify metastasis-regulating factors that act in a 
gain-of-function manner. Activation screens that identify oncogenes, as well as dropout 
screens that identify genetic dependencies, may facilitate identification of novel therapeutic 
targets. Targeted subpool strategies can be used to reduce the library size and facilitate 
further confirmation of primary screens. In a customized library, genes can be chosen based 
on genomic analysis, pathways, or clinical relevance for focused screening libraries. 
Additionally, application of pooled sgRNA libraries using individually barcoded cells will 
allow quantitative assessment of the robustness and significance of each candidate hit as 
well as enable analysis of the competitive dynamics amongst different perturbations. Taken 
together, Cas9-based in vivo screening establishes a new platform for functional genomic 
discovery.
Experimental Procedures
Generation of Cas9-GFP expression vector
A lentiviral vector, lenti-Cas9-NLS-FLAG-2A-EGFP (lentiCas9-EGFP), was generated by 
subcloning Cas9 into a lentiviral vector.
Pooled guide-only library cloning and viral production
The Cas9-GFP KPD cell line was transduced at a MOI of ~ 0.4 with a genome-wide 
lentiviral mouse CRISPR knockout guide-only library (Sanjana et al., 2014) containing 
67,405 sgRNAs (mGeCKOa, Addgene 1000000053) with at least 400-fold representation 
(cells per construct) in each infection replicate.
Animal work statement
All animal work was performed under the guidelines of Division of Comparative Medicine 
(DCM), with protocols (0411-040-14, 0414-024-17, 0911-098-11, 0911-098-14 and 
0914-091-17) approved by Massachusetts Institute of Technology Committee for Animal 
Care (CAC), and were consistent with the Guide for Care and Use of Laboratory Animals, 
National Research Council, 1996 (institutional animal welfare assurance no. A-3125-01).
Mice, tumor transplant and metastasis analysis in the primary screen
Untransduced or mGeCKOa-transduced Cas9-GFP KPD cells were injected subcutaneously 
into the right side flank of Nu/Nu mice at 3x107 cells per mouse. Transplanted primary 
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tumor sizes were measured by caliper. At 6 weeks post transplantation, mice were sacrificed 
and several organs (liver, lung, kidney and spleen) were dissected for examination of 
metastases under a fluorescent stereoscope.
Mouse tissue collection
Primary tumors and other organs were dissected manually. For molecular biology, tissues 
were flash frozen with liquid nitrogen, ground in 24 Well Polyethylene Vials with metal 
beads in a GenoGrinder machine (OPS diagnostics). Homogenized tissues were used for 
DNA/RNA/protein extractions using standard molecular biology protocols. Tissues for 
histology were then fixed in 4% formaldehyde or 10% formalin overnight, embedded in 
paraffin, and sectioned at 6 μm with a microtome as described previously (Chen et al., 
2014). Slices were subjected to hematoxylin and eosin (H&E) staining as described 
previously (Chen et al., 2014).
Genomic DNA extraction from cells and mouse tissues
Genomic DNA from cells and tissues (primary tumors and lungs) were extracted using a 
homemade modified salt precipitation method similar to the Puregene (Qiagen/Gentra) 
procedure. The sgRNA cassette was amplified and prepared for Illumina sequencing as 
previously described (Shalem et al., 2014). A detailed readout protocol can be found in 
Extended Experimental Procedures.
Individual gene and microRNA validation
Six sgRNAs per protein coding gene and four sgRNAs per microRNA gene were chosen for 
validation using individual sgRNAs (Table S4). For protein coding genes, we cloned gene. 
For microRNAs, we used all 4 sgRNAs from the mGeCKOa library.
Validation and control minipool synthesis and in vivo transplantation
Validation and control minipools (Tables S5) were synthesized using array oligonucleotide 
synthesis (CustomArray) and transduced at >1000-fold representation in Cas9-GFP KPD 
cells. After 7 days in culture, Cas9-GFP KPD cells transduced with the validation minipool 
or control minipool were injected subcutaneously into the right side flank of Nu/Nu mice at 
3x107 cells per mouse with 5 replicate mice. After five weeks, mice were sacrificed, and 
primary tumors and lungs were dissected.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Genome-wide in vivo screen using CRISPR/Cas9 in a mouse model of lung 
metastasis
• Identified loss-of-function mutations in known tumor suppressors and novel 
genes
• Targeted subpool as a pooled competition assay to validate genes from screen
• The effect of mutations on metastasis correlates with primary tumor abundance
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Figure 1. 
(A) Schematic representation of the loss-of-function metastasis screen using the mouse 
genome-scale CRISPR/Cas9 knock-out library (mGeCKOa).
(B) Representative hematoxylin and eosin (H&E) stains of primary tumor from Nu/Nu mice 
subcutaneously transplanted with a Cas9-GFP KrasG12D/+;p53−/−;Dicer1+/− (KPD) 
NSCLC cell line, untransduced or transduced mGeCKOa lentiviral library. Scale bar: 200 
μm.
(C) Primary tumor growth curve of Nu/Nu mice transplanted with untransduced cells (n = 3 
mice) or mGeCKOa-transduced Cas9-GFP KPD cells (n = 9 mice).
(D) Micro-CT 3D reconstruction of the lungs of representative mice transplanted with 
control (untransduced) and mGeCKOa-transduced (mGeCKOa) cell pools. Lung metastases 
were identified and traced in each 2D section (green).
(E) Percent of lobes with metastases visible after dissection under a fluorescence 
stereoscope, in Nu/Nu mice transplanted with untransduced Cas9-GFP KPD cells (n = 3 
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mice), or mGeCKOa-transduced Cas9-GFP KPD cells with three independent infection 
replicate experiments (R1, R2 and R3, n = 3 mice per replicate).
(F) Representative H&E stains from various organs of Nu/Nu mice subcutaneously 
transplanted with untransduced and mGeCKOa-transduced Cas9-GFP KPD cells. Yellow 
arrow indicates a lung metastasis. Scale bar: 40 μm.
(See also: Figure S1)
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Figure 2. 
(A) Pearson correlation coefficient of the normalized sgRNA read counts from the 
mGeCKOa plasmid library, transduced cells before transplantation (day 7 after spinfection), 
early primary tumors (~ 2 weeks after transplantation), late primary tumors (~ 6 weeks after 
transplantation), and lung metastases (~ 6 weeks after transplantation). For each biological 
sample type, 3 independent infection replicates (R1, R2 and R3) are shown. n = 1 mouse per 
infection replicate for early primary tumors and n = 3 mice per infection replicate for late 
primary tumors and lung samples.
(B) Number of unique sgRNAs in the plasmid, cells before transplantation, early and late 
primary tumors and lung metastases as in (A), Error bars for late primary tumors and lung 
metastases denote the s.e.m. for n = 3 mice per infection replicate.
(C) Boxplot of the sgRNA normalized read counts for the mGeCKOa plasmid pool, cells 
before transplantation, early and late primary tumors and lung metastases as in (A). Outliers 
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are shown as colored dots for each respective sample. Gray dots overlayed on each boxplot 
indicate read counts for the 1,000 control (non-targeting) sgRNAs in the mGeCKOa library. 
Distributions for late primary tumors and lung metastases are averaged across individual 
mice from the same infection replication.
(D) Cumulative probability distribution of library sgRNAs in the plasmid, cells before 
transplantation, early and late primary tumors and lung metastases as in (A). Distributions 
for each sample type are averaged across individual mice and infection replications.
(See also: Figures S2 and S3)
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Figure 3. 
(A) Pie charts of the most abundant sgRNAs in the primary tumors (at ~6 weeks post-
transplantation) of three representative mice (one from each replicate mGeCKOa infection). 
The area for each sgRNA corresponds to the fraction of total reads from the primary tumor 
for the sgRNA. All sgRNAs with ≥ 2% of total reads are plotted individually.
(B) Number of genes with 0, 1, 2 or 3 significantly enriched (FDR < 0.2% for at least one 
mouse) mGeCKOa sgRNAs targeting that gene. For genes/miRs with 2 or more enriched 
sgRNAs, genes/miRs are categorized by how many sgRNAs targeting that gene/miRs are 
enriched as indicated in the colored bubbles adjacent to each bar.
(C) Inset: Waterfall plot of sgRNAs where multiple sgRNAs targeting the same gene are 
significantly enriched in primary tumors. Each sgRNA is ranked by the percent of mice in 
which it is enriched. Only sgRNAs enriched in 2 or more mice are shown in the main panel. 
Main panel: Enlargement and gene labels for sgRNAs at the top of the list from the inset 
(boxed region).
(See also: Figures S3, S4 and S5)
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Figure 4. 
(A) Pie charts of the most abundant sgRNAs in three individual lobes of the lungs of two 
representative mice transplanted with mGeCKOa transduced cells. The area for each sgRNA 
corresponds to the fraction of total reads from the lobe for the sgRNA. All sgRNAs with ≥ 
2% of total reads are plotted individually.
(B) Pie charts of the most abundant sgRNAs in the lung (averaged across three individual 
lobes) for the two mice shown in (A). All sgRNAs with ≥ 2% of average reads are plotted 
individually.
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(C) Left: Percentage of late tumor reads for the significantly enriched (FDR < 0.2%) 
mGeCKOa sgRNAs found in the lung metastases (averaged across three dissected lobes). 
Right: In purple, the percentage of late tumor reads for the significantly enriched 
(FDR<0.2%) mGeCKOa sgRNAs found in the lung metastases (average across all mice, n = 
9 mice). In grey, the percentage of late tumor reads for random, size-matched samplings of 
sgRNAs present in the late tumor (n = 100 samplings).
(D) Inset: All sgRNAs found in individual lung lobes ordered by the percent of lobes in 
which a particular sgRNA was amongst the significantly enriched (FDR < 0.2%) sgRNAs 
for that lobe. Only sgRNAs enriched in 2 or more lobes are shown. Main panel: 
Enlargement and gene labels for sgRNAs at the top of the list from the inset (boxed region).
(E) Inset: All sgRNAs found in individual mouse (averaged across three dissected lobes) 
ordered by the percent of mice in which a particular sgRNA was amongst the significantly 
enriched (FDR < 0.2%) sgRNAs for that mouse. Only sgRNAs enriched in 2 or more mice 
are shown. Main panel: Enlargement and gene labels for sgRNAs at the top of the list from 
the inset (boxed region).
(F) Bottom: Metastasis Primary Ratio (MPR) for the sgRNAs in mGeCKOa with enrichment 
in metastases over late tumor (MPR > 1) observed in at least 3 mice. The sgRNAs are sorted 
by the number of mice in which the MPR for the sgRNA is greater than 1. Top: Number of 
mice in which the MPR for this sgRNA is greater than 1. In both panels, individual sgRNAs 
are labeled by gene target.
(G) Number of genes with 0, 1, 2 or 3 significantly enriched (FDR < 0.2% for at least one 
mouse) mGeCKOa sgRNAs in the lung metastases. For genes with 2 enriched sgRNAs, 
gene names are indicated in the colored bubble adjacent to the bar.
(H) Number of mice and percentage of mice in which each sgRNA was enriched in the lung 
metastases for all genes with multiple enriched sgRNAs.
(See also: Figures S4 and S5)
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Figure 5. 
(A) Schematic representation of lentiviral transduction of Cas9-GFP KPD cells with single 
sgRNAs designed to target one gene or miR. After puromycin selection, the cell population 
was transplanted into Nu/Nu mice and also deep sequenced to examine the distribution of 
indels at the target site. After 5 weeks, the primary tumor and lungs are examined.
(B) Histograms of indel sizes at the genomic locus targeted by a representative sgRNA for 
each gene/miR after 3 days of puromycin selection. Indels from sgRNAs targeting the same 
gene were pooled (6 sgRNAs for each protein-coding gene, 4 sgRNAs for each miR).
(C) Representative H&E staining of lung lobes from uninjected mice (n = 3 mice), mice 
transplanted with cells transduced with Cas9 only (n = 5), and mice transplanted with cells 
containing Cas9 and a single sgRNA (n = 6). Single sgRNAs are either control/non-targeting 
sgRNAs (n = 6 mice for control sgRNAs, 3 distinct control sgRNAs with 2 mice each) or 
targeting sgRNAs (n = 6 mice for each gene/miR target, 3 sgRNAs per target with 2 mice 
each). Blue arrows indicate lung metastases. Scale bar: 10 μm.
(D) Percent of lung lobes with metastases after 6 weeks for the mice in (C).
(E) Primary tumor growth curve of Nu/Nu mice transplanted with NSCLC cells transduced 
with Cas9 only (n = 5) or single sgRNAs (n = 6 mice per gene/miR target, 3 sgRNAs per 
target with 2 mice each; n = 6 mice for control sgRNAs, 3 control sgRNAs with 2 mice 
each).
(F) Correlation between primary tumor volume and percent of lobes with metastases for 
each gene in (D) and (E). Error bars indicate s.e.m..
(See also: Figure S6)
Chen et al. Page 25
Cell. Author manuscript; available in PMC 2016 March 12.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. 
(A) Schematic representation of the loss-of-function metastasis minipool screen. Briefly, 
Cas9-GFP KPD cells were transduced with either validation minipool (524 gene-targeting + 
100 non-targeting sgRNAs) or control minipool (624 non-targeting sgRNAs). After 
puromycin selection, the cell pools are transplanted into Nu/Nu mice. After 6 weeks, 
validation minipool sgRNAs are sequenced from primary tumor and lung samples.
(B) Primary tumor growth curve of Nu/Nu mice transplanted with Cas9 vector + validation 
minipool cells (n = 5 mice) or Cas9 + control minipool cells (n = 5 mice).
(C) Percent of lung lobes with metastases after 6 weeks for the mice in (B). C = control 
minipool. V = validation minipool.
(D) Boxplot of the sgRNA normalized read counts for the plasmid library, cells before 
transplantation, primary tumor and lung metastases using the validation minipool.
(E) Cumulative probability distribution of library sgRNAs in the validation plasmid pool, 
cells before transplantation, early tumor and lung metastases. Distributions of primary tumor 
and lung metastases are averaged across 5 mice.
(See also: Figure S7)
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Figure 7. 
(A) Pie charts of the most abundant sgRNAs in the primary tumor and the whole lung of two 
representative mice transplanted with validation minipool transduced Cas9-GFP KPD cells. 
The area for each sgRNA corresponds to the fraction of total reads from the tissue (primary 
tumor or lung metastases) for the sgRNA. All sgRNAs with ≥ 2% of total reads are plotted 
individually.
(B) Scatterplot of normalized sgRNA read counts in primary tumor and lung metastases for 
all sgRNAs in the validation minipool for each mouse (different color dots indicate sgRNAs 
from different mice). log2 n.r., log2 normalized reads.
(C) log2 ratio of sgRNA abundance in the lung metastases over the primary tumor 
(Metastasis-Primary Ratio, or MPR) plotted against the abundance in the lung metastases (n 
= 5 mice per sgRNA). Green dots are the 100 control sgRNAs. Dots with black outlines are 
non-control sgRNAs that target genes or miRs. Red dots indicate non-control sgRNAs for 
which more than one sgRNA targeting the same gene/miR is enriched in the lung metastases 
over the primary tumor (i.e. log2(MPR) > 0 ) and are labeled with the gene/miR targeted. 
The lung-primary ratio is calculated for individual mice and these quantities are averaged 
across mice.
(D) Number of genes with 0 to 10 significantly enriched validation minipool sgRNAs in 
lung metastases. For genes/miRs with 2 or more enriched sgRNAs, genes/miRs are 
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categorized by how many sgRNAs targeting that gene/miRs are enriched as indicated in the 
colored bubbles adjacent to each bar.
(E) Schematic illustration of tumor growth and metastasis in the library-transduced NSCLC 
transplant model. The initially diverse set of loss-of-function mutations in the 
subcutaneously transplanted pool is selected over time for mutations that promote growth of 
the primary tumor. A subset of these mutants also dominate lung metastases.
(See also: Figure S7)
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